High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
Marta Palafox,Laia Monserrat,Meritxell Bellet,Guillermo Villacampa,Abel González-Pérez,Mafalda Oliveira,Fara Brasó-Maristany,Nusaïbah Ibrahimi,Srinivasaraghavan Kannan,Leonardo Mina,María Teresa Herrera-Abreu,Andreu Òdena,Mònica Sánchez-Guixé,Marta Capelán,Analía Azaro,Alejandra Bruna,Olga Rodríguez,Marta Guzmán,Judit Grueso,Cristina Viaplana,Javier Hernández‐Losa,Faye Su,Kui Lin,Robert Clarke,Carlos Caldas,Joaquı́n Arribas,Stefan Michiels,Alicia García-Sanz,Nicholas C. Turner,Aleix Prat,Paolo Nuciforo,R. Dienstmann,Chandra Verma,Núria López‐Bigas,Maurizio Scaltriti,Mónica Arnedos,Cristina Saura,Violeta Serra Research Square (Research Square)（2021）
Key words
high p16 expression,heterozygous rb1 loss,breast cancer,biomarkers
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper